Results 211 to 220 of about 14,856,428 (286)

BrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma

British Journal of Haematology, EarlyView.
BrECADD can be delivered over 3 days instead of four, reducing intravenous treatment days by 25% without compromising dose intensity. Among 30 patients with advanced‐stage Hodgkin lymphoma, no unexpected toxicity was observed; there were no early discontinuations, and 1‐year progression‐free and overall survival were both 100%.
Christian Peter Jaworek, Maja Supprian, Paul Jan Bröckelmann, Hishan Tharmaseelan, Justin Ferdinandus, Dennis A. Eichenauer, Anne Sophie Robertz, Janina Jablonski, Vincent Combüchen, Jan‐Oliver Staak, Karin Töpelt, Jan‐Michel Heger, Jon Rischewski, Jannik Stemler, Wolfram Klapper, Peter Borchmann, Bastian von Tresckow   +16 more
wiley   +1 more source

Diffuse large B‑cell lymphoma followed by myelodysplastic syndrome with TP53 mutation: a case report and literature review. [PDF]

Front Oncol
Wu X, Zhao J, Fan Y, Yang X, Yang X.
europepmc   +1 more source

Predicted microbiome‐associated metabolic pathways are linked to immune checkpoint modulation in chronic lymphocytic leukaemia

British Journal of Haematology, EarlyView.
Summary Microbial metabolites are key regulators of host immunity, yet their functional impact in chronic lymphocytic leukaemia (CLL) remains unclear. Following up on our earlier observations of microbiome dysbiosis in CLL, we performed predictive metabolic profiling based on 16S ribosomal RNA (rRNA) sequencing of oral and stool samples collected from ...
Monika Szelest, Joanna Zaleska, Michał Kiełbus, Magdalena Paziewska, Marta Masternak, Ewa Wawrzyniak, Aleksandra Kotkowska, Monika Siemieniuk‐Ryś, Marta Morawska, Elżbieta Kalicińska, Paula Jabłonowska‐Babij, Tomasz Wróbel, Anna Wolska‐Washer, Jerzy Zdzisław Błoński, Tadeusz Robak, Krzysztof Giannopoulos   +15 more
wiley   +1 more source

Dynamic risk stratification using early CAR‐T expansion in R/R LBCL treated with axicabtagene ciloleucel

British Journal of Haematology, EarlyView.
Higher chimeric antigen receptor‐T expansion at day 7 is associated with improved progression‐free survival but also increased toxicity in axi‐cel treated patients with R/R large B‐cell lymphoma, independent of other baseline patient and disease characteristics.
Brydon Panozzo, Samuel Robinson, Adrian G. Minson, Jian Li, Kylie Baldwin, Hamish W. Scott, Jane Oliaro, Aaron J. N. Wong, Samantha van der Linde, Nicole L. O'Leary, Philip A. Thompson, John F. Seymour, Mary Ann Anderson, Constantine S. Tam, Simon J. Harrison, Michael J. Dickinson, David A. Westerman, Mark R. Dowling   +17 more
wiley   +1 more source

Real-world efficacy and safety of golidocitinib in 3 patients with relapsed/refractory peripheral T-cell lymphoma. [PDF]

Front Oncol
Wang B, Yu F, Wang Y, Mao X, Li J, Li J, Jin Z, Li L, Huang Y.   +8 more
europepmc   +1 more source

A phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial

British Journal of Haematology, EarlyView.
The AVAIL‐T study, the first evaluation of programmed death ligand 1 (PD‐L1) blockade in relapsed/refractory peripheral T‐cell lymphomas (PTCL), demonstrated limited single agent activity with durable responses seen in a minority. Circulating tumour DNA revealed distinct mutational dynamics and mass cytometry identified perturbed T‐cell subsets ...
Matthew J. Ahearne, Matthew A. Timmins, Charlotte Gaskell, Aimee Jackson, Clare Morland, Sonia Fox, Louise Hopkins, Nadia Nawaz, Susann Lehmann, Marc Wadsley, Caroline Cowley, Jacqueline Shaw, Naeem Khan, Nagesh Kalakonda, Christopher Trethewey, Ram Malladi, Paul Fields, Dima El Sharkawi, Michael Quinn, Nimish Shah, Andrew Davies, Kim Linton, Pam McKay, Rod Johnson, Simon D. Wagner, David Lewis, Graham P. Collins, Christopher P. Fox, Kate Cwynarski   +28 more
wiley   +1 more source

Model-Based Analysis with Mechanistic Insights to CAR-T-Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel. [PDF]

Clin Pharmacol Ther
Mc Laughlin AM, Bergstrand M, Ruiz-Garcia A, Filosto S, Shen R.   +4 more
europepmc   +1 more source

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

British Journal of Haematology, EarlyView.
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz, Rémi Letestu, Mary Sartor, Stephen Mulligan, Marie C. Béné, Gavin Cull, Dennis Carney, William Renwick, Andrew Grigg, Cecily Forsyth, Gregory Hapgood, Emma Verner, Rosemary Harrup, Pauline Warburton, Kylie Mason, Richard Eek, Wojciech Janowski, Jean Pierre Vilque, Maya Latimer, Laurent Voillat, Sophie De Guibert, Bernard Drenou, Robert Blum, Caroline Dartigeas, Lachlan Hayes, Nicolas Daguindau, Mourad Tiab, Véronique Leblond, Andrew Shearer, Masa Lasica, Pierre Morel, Bohrane Slama, Anne Banos, Annie Brion, Emmanuelle Ferrant, Jessica Michel, Cécile Tomowiak, Edward Morris, Hanlon Sia, Kelly Kratzing, Belinda E. Butcher, Abdelmalek Dahmani, Stephen Robert Larsen, Piers Blombery, Florence Cymbalista, David J. Gottlieb   +45 more
wiley   +1 more source

Real-world outcomes of T cell lymphoma in a tertiary cancer center in Saudi Arabia. [PDF]

Ann Saudi Med
Alqahtani S, Assiri M, Abdu AB, Alyusif K, Alharbi M, Alharbi Z, Alsubaie A, Alhamzani A, Alghamdi S, Alshibani S.   +9 more
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source